Clinical Research Directory
Browse clinical research sites, groups, and studies.
Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes
Sponsor: Zagazig University
Summary
This randomized controlled trial evaluates the efficacy of three weekly GLP-1 receptor agonists (dulaglutide, semaglutide, and tirzepatide) in non-diabetic obese adults. 150 participants with BMI \>30 will be randomized into three groups and followed for 6 months to assess changes in weight, BMI, lipid profile, and liver functions.
Official title: Evaluating the Efficacy of Various Weekly GLP1receptor Agonist Among Obese Individuals Without Diabetes
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2025-11-14
Completion Date
2026-04-21
Last Updated
2026-09-22
Healthy Volunteers
Yes
Conditions
Interventions
Dulaglutide
weight control drug dulaglutide 1.5 mg subcutaneous injection GLP-1 receptor agonist
Semagludtide
Weight control drug semaglutide 2.4 mg subcutanous injection GLP-1 receptor agonist
Tirzepatide
Weight control drug tirzepatide 15 mg subcutanous injection GLP-1 receptor agonist
Locations (1)
New Najran General Hospital
Najran, Saudi Arabia